In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Biogen trades well below a high-confidence fair value of $425.22, indicating significant upside potential with limited downside risk per Monte Carlo analysis. Strong liquidity contrasts with moderate profitability, efficiency, and growth scores, highlighting operational challenges. Valuation dispersion and high volatility signal notable uncertainty despite favorable base case estimates.